Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Souvenaid

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

- PMLiVE

Longevity lessons

The secret to corporate longevity isn’t growth, it’s survival

- PMLiVE

Pfizer to supply 6 million Paxlovid treatments to low- and middle-income countries

Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach

- PMLiVE

EC approves Alexion’s Ultomiris as generalised myasthenia gravis treatment

The positive phase 3 trial results assessing the treatment were published in NEJM Evidence

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

Merck to initiate phase 3 HIV-1 clinical programme with a lower dose of islatravir

A phase 2 study evaluating islatravir with Gilead’s lenacapavir will also resume with the lower dose

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

It’s a Medscape wrap for #EADVCongress

Medscape was on-site at this year’s EADV conference in Milan, with educational activities and a booth to connect with healthcare professionals.At our booth, we spoke with attendees about Medscape and...

Medscape Education

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17...

Impetus Digital

- PMLiVE

The fight against antimicrobial resistance

By Jonathan Cooke

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links